Author:
Kesselheim Aaron S.,Gagne Joshua J.
Publisher
Springer Science and Business Media LLC
Reference8 articles.
1. Coté T, Kelkar A, Xu K, Braun MM, Phillips MI. Orphan products: an emerging trend in drug approvals. Nat Rev Drug Discov. 2010;9(1):84.
2. NIDDK. National diabetes statistics. 2011. Available at: http://diabetes.niddk.nih.gov/dm/pubs/statistics/ .
3. Kesselheim AS. Innovation and the Orphan Drug Act, 1983–2009: the regulatory and clinical characteristics of approved orphan drugs. In: Field MJ, Boat TF, eds. Accelerating Rare Diseases Research and Orphan Product Development. Washington, DC: National Academy Press; 2010.
4. Joppi R, Bertele’ V, Garattini S. Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU. Eur J Clin Pharmacol. 2013;69(4):1009–24.
5. Kesselheim AS. An empirical review of major legislation affecting drug development: past experiences, effects, and unintended consequences. Milbank Q. 2011;89(3):450–502.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献